Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Roche Holding AG

Market Cap 263B 330B 285B 246B 461B 31,407B 468B 3,105B 1,211B 15,287B 1,240B 1,214B 52,930B P/E Ratio 2026 *
17.7x
P/E Ratio 2027 * 16.5x
Enterprise Value 273B 343B 297B 256B 479B 32,638B 487B 3,227B 1,258B 15,886B 1,289B 1,261B 55,006B EV / Sales 2026 *
4.37x
EV / Sales 2027 * 4.09x
Free-Float
88.78%
Yield 2026 *
3.04%
Yield 2027 * 3.11%
1 day+1.44%
Current month+2.39%
3 months+2.39%
6 months+2.52%
Current year+0.55%
Current year 315.6
Extreme 315.6
374.9
1 year 243.9
Extreme 243.9
374.9
3 years 212.9
Extreme 212.9
374.9
5 years 212.9
Extreme 212.9
404.2
10 years 206.35
Extreme 206.35
404.2
Manager TitleAgeSince
Chief Executive Officer 51 15/03/2023
Director of Finance/CFO 59 06/06/2011
Chief Operating Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 68 01/01/1996
Chairman 59 15/03/2023
Director/Board Member 73 03/03/2015
Change 5-day change 1-year change 3-year change Capi.($)
+1.44%+0.89% - - 330B
-2.41%+0.14%+38.28%+154.20% 1,010B
+1.07%+3.48%+53.32%+49.85% 580B
+1.32%+0.22%+19.18%+64.65% 402B
+0.44%+3.48%+25.65%+35.66% 281B
-0.85%-2.86%+22.54%+14.67% 280B
+1.66%+1.20%-44.35%-47.35% 197B
+0.32%+1.61%+20.32%+60.01% 192B
-0.22%-2.76%+14.19%+60.09% 156B
+0.15%+0.65%+6.81%-34.93% 149B
Average +0.29%+0.57%+17.33%+39.65% 360.88B
Weighted average by Cap. -0.15%+0.81%+27.46%+71.17%

Financials

2026 *2027 *
Net sales 62.58B 78.63B 67.91B 58.58B 110B 7,474B 111B 739B 288B 3,638B 295B 289B 12,596B 65.13B 81.84B 70.68B 60.97B 114B 7,779B 116B 769B 300B 3,786B 307B 301B 13,109B
Net income 15.16B 19.04B 16.45B 14.19B 26.59B 1,810B 27B 179B 69.78B 881B 71.47B 69.95B 3,051B 16.22B 20.38B 17.6B 15.18B 28.45B 1,937B 28.9B 192B 74.68B 943B 76.49B 74.86B 3,265B
Net Debt 10.31B 12.96B 11.19B 9.65B 18.09B 1,232B 18.37B 122B 47.48B 599B 48.63B 47.6B 2,076B 3.44B 4.32B 3.73B 3.22B 6.03B 411B 6.12B 40.59B 15.83B 200B 16.21B 15.87B 692B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Date Price Change Volume
12/06/26 330.00 CHF +1.44% 1,125,149
11/06/26 325.30 CHF +0.43% 1,371,862
10/06/26 323.90 CHF +1.60% 1,329,930
09/06/26 318.80 CHF -1.21% 1,844,589
08/06/26 322.70 CHF -1.35% 626,869
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
330.00CHF
Average target price
360.76CHF
Spread / Average Target
+9.32%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!